Results of the prognostic factor analysis of patients in the anlotinib group (multivariate analysis)

Item	PFS		OS
Item	P	HR (95%CI)	P	HR (95%CI)
Post-treatment ECOG score			0.002	2.073 (1.315, 3.269)
Post-treatment granulocytes/lymphocytes ratio	< 0.001	2.183 (1.523, 3.130)	< 0.001	2.423 (1.642, 3.576)
Pre-randomization maximal target lesion length			0.003	1.690 (1.190, 2.400)
Hypertension	0.040	0.688 (0.481, 0.983)
Hand-foot syndrome	0.002	0.582 (0.415, 0.815)
Hyperglycemia	0.007	0.632 (0.453, 0.884)
Hypertriglyceridemia	0.002	0.545 (0.569, 1.535)	0.002	0.520 (0.347, 0.778)
Elevated thyroid stimulating hormone	0.003	0.573 (0.399, 0.822)
Elevated alkaline phosphatase	0.044	1.425 (1.010, 2.011)